Tystatin

Quick links to important sections

Tystatin

Treatment option: Infection, Oral Cavity

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tystatin

Tystatin is a dedicated prescription-only medicine containing the active substance nystatin, primarily defined as a specialized polyene antifungal agent. Its core identity is that of a localized treatment, focusing its potent action directly on the sites of fungal infection with minimal systemic absorption.

Property Description
Active Ingredient Nystatin
Form Oral Suspension, Oral Tablet, Topical Cream, Vaginal Suppository
Pharmacological Class Polyene Antifungal / Polyene Macrolide
General Purpose To clear localized fungal overgrowth (Candidiasis)
Origin Naturally derived (from Streptomyces noursei)

Core Definition and Pharmacological Classification

Tystatin is classified as a polyene antifungal agent, a designation that clearly positions it against fungi and yeasts. The active ingredient, nystatin, belongs to the broader structural group of polyene macrolide antibiotics, which reflects its potent, targeted mechanism. The general purpose of Tystatin is to manage and control infections caused by susceptible fungi, most notably various forms of candidiasis.

Composition, Origin, and Selective Action

The compound nystatin is a naturally derived substance, originally isolated from the metabolic processes of the bacterium Streptomyces noursei, differentiating it from fully synthetic agents. This single-active ingredient product is available in multiple pharmaceutical forms to ensure targeted administration across different anatomical sites. Nystatin undergoes very little systemic absorption following oral or topical administration, limiting its efficacy to the treatment or prevention of localized fungal infections. This characteristic is a key differentiating factor, making the medicine suitable for managing infections such as mucocutaneous candidiasis without relying on systemic distribution.

Its mechanism involves a highly selective action where nystatin directly targets and binds to ergosterol, a sterol component unique to the fungal cell membrane, causing rapid cellular disruption and elimination of the fungal overgrowth.

Regulatory References

  1. NIH LiverTox (Nystatin)
  2. Nystatin's mechanism of action on ergosterol

What side effects are possible with Tystatin?

Possible side effects and safety information

The safety profile of Tystatin (nystatin) is primarily defined by reactions related to its localized action and minimal systemic absorption, according to official regulatory documentation. Adverse reactions are grouped by the affected organ system and classified by frequency based on clinical data.


Documented Adverse Reactions and Frequency

The majority of documented effects involve the gastrointestinal tract and local irritation, reflecting the drug’s site of application.

Frequency Category Associated Adverse Reactions
Uncommon Diarrhoea, abdominal discomfort, nausea, vomiting
Rare Hypersensitivity, angioedema (including facial oedema), Urticaria
Very Rare Stevens-Johnson syndrome (SJS)

Serious adverse reactions, though rare, include severe cutaneous events like Stevens-Johnson syndrome and significant hypersensitivity reactions such as angioedema (swelling).


Safety Considerations and Restrictions

Official labeling contains specific notes on safety for particular groups. For patients with renal impairment, significant nystatin plasma concentrations may occasionally occur following oral administration, a deviation from the usual negligible absorption. The drug is contraindicated in individuals with a history of hypersensitivity to nystatin or any component of the formulation.

The medicine is strictly not to be used for the treatment of systemic mycoses (widespread fungal infections). Furthermore, treatment should be discontinued if sensitization or irritation is reported during use. Safety information also notes that oral doses exceeding five million units daily have been associated with nausea and gastrointestinal upset.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived solely from official government regulatory sources, detailing documented overdose manifestations and mandated emergency actions for Tystatin (nystatin).


Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations Primarily mild and transitory gastrointestinal symptoms, including nausea and vomiting.
Physiological systems affected (as stated in label) Gastrointestinal system (GI); systemic toxicity is not expected due to negligible absorption.
Dose-related or exposure-related factors Oral doses in excess of five million units daily have caused the documented gastrointestinal symptoms.
Population-specific overdose notes No specific heightened risks or unique manifestations are described for particular populations.

Emergency Actions and Required Assistance

Category Regulatory Statement
Emergency-response statements Seek professional assistance or contact a Poison Control Center immediately in case of suspected overdosage or accidental ingestion.
When immediate medical help is required Contact emergency services immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Official overdose statements:

The regulatory profile for Tystatin confirms that systemic toxicity is not anticipated because nystatin undergoes minimal absorption from the digestive tract. Despite the low risk of systemic complications, mild gastrointestinal upset and nausea have been associated with high oral doses.

No specific antidote is known. The official guidance requires that individuals immediately seek professional assistance or contact a Poison Control Center for medical advice in case of suspected overdosage. When severe, life-threatening symptoms such as collapse or seizure occur, emergency services must be contacted immediately.

Therapeutic Uses of Tystatin

Quick Facts

  • Oral Cavity: Used in the management of candidiasis (yeast infection) in the mouth, often called oral thrush.
  • Gastrointestinal Tract: Employed for certain infections of the stomach and intestinal lining.
  • Mucous Membranes: May be used to help address non-esophageal candidiasis involving mucous membranes.

Tystatin is a medication approved for use in addressing certain fungal infections caused by Candida species. Its primary application involves the management of candidiasis, commonly known as oral thrush, within the oral cavity. For individuals experiencing this type of infection, Tystatin may be used to support the resolution of the condition.

The medication may also be indicated for use in the management of certain Candida infections that affect the lining of the stomach and intestines. Unlike treatments that work systemically throughout the body, Tystatin is primarily intended for topical activity within the digestive tract, as its absorption into the bloodstream is limited. Treatment is often prescribed to continue for a specific time after clinical signs have lessened to help prevent recurrence. Tystatin is an option within a comprehensive therapeutic plan.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tystatin — Official Regulatory Information

The eligibility status for Tystatin (nystatin) is defined by its localized action, resulting in minimal systemic absorption, as documented in official government regulatory documents.


Eligibility Scope

Criteria Status or Restriction (Per Label)
Populations Contraindicated Patients with a history of hypersensitivity to nystatin or any formulation component.
Prohibited Use Must not be used for systemic fungal infections due to negligible absorption.
Age-Related Rules Established for adults, children, and neonates. The oral suspension is appropriate for infants and low-birth-weight infants.
Pregnancy Status Conditional: Classified as Pregnancy Category C (US FDA). Use is authorized only if clearly needed.
Lactation Status Caution should be exercised as it is not known whether nystatin is excreted in human milk.
Conditional Use Patients with renal insufficiency receiving oral therapy, as significant plasma concentrations may occasionally occur.

Connection to the overall eligibility profile

Regulatory documents strictly define eligibility based on the absolute contraindication of known hypersensitivity and the drug’s fundamental localized action. Because Tystatin is negligibly absorbed systemically, regulatory labeling prohibits its use for deep-seated or systemic fungal infections. Eligibility is established for all age groups, while use in pregnant women and those who are nursing is conditional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented drug and product interactions for Tystatin, based solely on authoritative regulatory labeling.


Contraindicated Combinations

Co-administration with potent CYP3A4 inhibitors and specific drugs highly dependent on the CYP3A4 enzyme for clearance is strictly contraindicated. This includes medicines like Simvastatin and Lovastatin where elevated levels pose significant risk. Similarly, the use of potent CYP3A4 inducers, such as Rifampin, is contraindicated due to the potential for Tystatin therapeutic failure.

Pharmacokinetic and Pharmacodynamic Interactions

Official documents describe Tystatin as a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4, which can significantly increase the systemic exposure (AUC/Cmax) of co-administered substrates like Warfarin and Cyclosporine. Additionally, a pharmacodynamic interaction exists with other agents that increase the risk of myopathy or rhabdomyolysis (e.g., Fibrates), necessitating extreme caution.

Product and Timing Constraints

Consumption of Grapefruit juice is documented to increase Tystatin levels, while St. John's Wort is known to decrease them, leading to specific restrictions. Tystatin doses may require separation by several hours from certain Bile Acid Sequestrants to prevent interference with absorption, as specified in regulatory guidance. Interaction monitoring and potential dosage adjustments are noted for patients with renal or hepatic impairment.

Mechanism of Action

Selective Targeting of Fungal Ergosterol

Tystatin's mechanism begins with a specific molecular recognition event: the active substance, nystatin, exhibits a strong, preferential binding affinity for ergosterol, a sterol found exclusively in the membrane of fungal cells. This selective targeting results in the molecule's action being directed against the pathogen, which uses cholesterol instead of ergosterol.


Disruption via Ion Channel Formation and Cell Lysis

Upon binding to ergosterol, multiple nystatin molecules aggregate within the fungal membrane to form rigid, aqueous pores or channels. These pores immediately compromise the fungal cell's integrity, leading to an uncontrolled leakage of essential intracellular ions, such as potassium ( K^+), which collapses the cell's electrochemical and osmotic balance. This mechanistic cascade results in the physical lysis of the fungal cell (a fungicidal effect).


Functional Constraint to Localized Action

This mechanism is functionally constrained by the molecule's physical properties, leading to negligible systemic absorption after administration. Consequently, the fungicidal action is restricted to the specific local site of contact.

Dosage and Administration Information

How Tystatin Is Used

Tystatin (nystatin) is administered via localized routes only, reflecting its minimal systemic absorption and its primary function as a surface-acting antifungal agent. Usage is standardized across multiple forms to ensure direct contact with the site of fungal overgrowth.

Official Administration and Dosage

Administration Route Standard Adult Dose Frequency and Timing
Oral Suspension (for mouth/pharynx) 400,000 to 600,000 units per dose Four times a day (q.i.d.); often between meals.
Oral Tablet (for intestinal use) 500,000 to 1,000,000 units per dose Three times a day (t.i.d.).
Topical (Cream/Ointment) Apply liberally to affected area Two to three times a day.

Procedural Instructions and Course Duration

Specific preparation and administration techniques are defined for proper use. The oral suspension must be shaken well before measurement to ensure uniform concentration. For treating the mouth and throat, the suspension dose must be divided and retained in the mouth as long as possible before swallowing to coat the infection site.

For most indications, treatment should continue for a full course, typically 7 to 14 days, and must be extended for at least 48 hours after clinical symptoms have fully disappeared.

Pediatric Dosing: Lower unit doses are specified for infants, who typically receive 200,000 units per dose of the oral suspension, administered in the same divided, local-contact method.

Recent Clinical Evidence

Tystatin: Recent Clinical Evidence

Evidence for Use in Oropharyngeal Candidiasis

Research has explored Tystatin in the context of candidiasis, a condition where symptoms may vary in intensity in the mouth. Studies, primarily short-term Randomized Controlled Trials (RCTs) and systematic reviews, measured outcomes related to physical discomfort and the mycological cure rate (measured reduction of Candida). Findings describe patterns observed over initial treatment periods. However, evidence quality varies across studies due to formulation differences, and comparative evidence is lacking or subgroup findings are uncertain when measured against systemic agents in some patient groups.

Evidence for Use in Non-Invasive Gastrointestinal Candidiasis

Tystatin was studied for its application against candidiasis localized within the GI tract and for study scenarios exploring prophylaxis. Because the active ingredient undergoes minimal systemic absorption, studies focused on non-invasive infections. Outcomes monitored included the measured clearance of Candida and, in preventive studies, measures related to the occurrence of systemic fungal infections. Evidence remains limited in broader adult populations for established GI candidiasis, often relying on older, descriptive studies.

Analysis of Evidence in Special Populations

Research has explored Tystatin's use in specific cohorts, including children and infants, older adults with denture candidiasis, and immunocompromised patients. For high-risk groups, findings were mixed, and it is not yet clear whether observed patterns are similar to those in otherwise healthy adults. Comparative evidence is lacking against systemically absorbed treatments in these high-risk settings.

Durability of Response and Long-Term Studies

The research is characterized predominantly by follow-up durations that were limited, often assessing outcomes over one to two weeks. Long-term effects are not fully established, and much of the existing data provides only insight into short-term changes.

Areas of Research Uncertainty and Study Limitations

The overall evidence base includes limitations such as modest sample sizes in older trials. A significant gap remains in comparative evidence against newer systemic antifungal treatments, particularly for high-risk patients. Follow-up durations were limited, and data for certain groups remain insufficient to draw conclusions about maintenance study scenarios.

Key Studies & References

  1. Nystatin Oral Suspension FDA Label / DailyMed Monograph for Candidiasis Treatment
  2. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis
  3. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Tystatin (FAQ)

Q: How quickly should I expect Tystatin to start working?

A: Symptomatic improvement often begins within a few days of starting Tystatin. However, official information stresses the importance of completing the full course of therapy as prescribed. Stopping treatment early may be associated with the return of the infection, according to prescribing guidance.

Q: Does Tystatin interact badly with common pain relievers like ibuprofen?

A: Regulatory information primarily focuses on potential interactions between Tystatin and certain prescription medications that affect liver enzymes (CYP450). Common over-the-counter pain relievers, such as ibuprofen, are generally not listed as having specific, established interactions with nystatin in official drug labels. Patients with concerns about interactions should review all their medications with a healthcare provider.

Q: Can Tystatin cause fatigue or make you sleepy?

A: Fatigue or excessive sleepiness are generally not listed as common or serious adverse reactions in the official regulatory documents for Tystatin. The documented side effects primarily involve localized reactions and effects on the stomach and intestines, which reflects the drug’s minimal absorption into the bloodstream.

Q: Do I need to avoid any specific foods or drinks while on Tystatin?

A: Official guidance notes that interactions can occur with grapefruit juice and the herbal supplement St. John's Wort. For the oral suspension, patients are often advised to avoid eating or drinking for a short time after administration to allow the medication to coat the infected area properly. Beyond these specifics, there are generally no major food restrictions listed.

Q: If I miss a dose of Tystatin, what should I do?

A: According to the patient information, if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Official guidance recommends against taking two doses at the same time.

Q: Is it normal to feel a mild headache when starting Tystatin?

A: Headache is generally not listed as a documented adverse reaction in the official regulatory documents. Tystatin's side-effect profile is dominated by gastrointestinal and local effects due to its action being restricted to the infection site. Patients who experience a persistent or concerning headache should contact a healthcare provider for guidance.

Q: Can children take Tystatin, and is the dose different?

A: Yes, Tystatin oral suspension is indicated for use in all age groups, including infants, children, and adults. Official guidance confirms that the specific unit amount administered may differ between infants, children, and adults.

Q: Can Tystatin make my stomach upset or cause nausea?

A: Yes, regulatory documents list gastrointestinal symptoms as common adverse reactions. These documented effects include nausea, vomiting, diarrhea, and general abdominal discomfort, reflecting the drug's localized activity in the digestive tract.

Q: Are there any known interactions between Tystatin and alcohol?

A: Official regulatory documents do not typically list specific interactions between nystatin and alcohol. It is worth noting that some liquid formulations may contain a small amount of alcohol as an inactive ingredient. It is important for patients to review all potential interactions with a healthcare professional.

Q: Do you have to take Tystatin with food or on an empty stomach?

A: For the oral suspension used to treat infections in the mouth, administration is often recommended between meals to maximize contact time with the infected area. For other forms, such as the oral tablet, specific requirements to take it with food or on an empty stomach are not typically stated in official labeling.

Q: What happens if I stop taking Tystatin suddenly?

A: The full prescribed course of treatment is recommended, even if the symptoms of the infection clear up quickly. Discontinuing treatment early may result in the infection returning, according to patient guidance.

Q: Can Tystatin be used during pregnancy or while breastfeeding?

A: Use during pregnancy is authorized only when considered clearly needed by a healthcare provider, as Tystatin is classified as Pregnancy Category C. Because it is not known whether nystatin is excreted in human milk, caution is advised when used by women who are nursing.

Q: Is Tystatin safe for people with kidney disease?

A: Caution is noted for individuals with renal (kidney) insufficiency who are receiving oral therapy. This is due to the potential for a small, significant concentration of nystatin to enter the bloodstream, which is a rare deviation from its usual minimal absorption. Renal function may require monitoring in these patients.

Q: How long does Tystatin stay in your system after you stop taking it?

A: Due to Tystatin's minimal systemic absorption, the majority of the dose is not absorbed into the bloodstream. It passes through the body unchanged via the stool, meaning it is not subject to significant metabolism and does not typically accumulate in the body after administration is stopped.

Q: Is Tystatin considered a 'maintenance' drug or a short-term treatment?

A: Tystatin is intended for a full, short course of treatment, typically lasting 7 to 14 days, which must be extended until all symptoms have been gone for at least 48 hours. It is not generally defined as a long-term maintenance drug in regulatory documents.

Q: What kind of research has been done on Tystatin's long-term safety?

A: Official regulatory information states that no long-term animal studies have been conducted to evaluate the potential of nystatin to cause cancer (carcinogenesis) or to determine its effects on fertility or genetic damage (mutagenicity) following oral administration.

Q: What should I do if I experience a rare or unexpected side effect from Tystatin?

A: Patients should notify a healthcare provider immediately if they experience symptoms of local irritation, sensitization, or unexpected reactions during treatment. For serious adverse events, official guidance directs patients and professionals to report them to the relevant national regulatory body.

Q: Is it possible to be allergic to Tystatin?

A: Yes, official labeling strictly contraindicates the use of Tystatin in anyone with a known history of hypersensitivity or allergy to nystatin or any component of the formulation. Hypersensitivity reactions, including swelling (angioedema) and rash, have been reported.

Q: What happens if I take Tystatin and an antacid at the same time?

A: Specific interactions between Tystatin and common antacids are not usually listed in the official drug labels. As a general precaution against affecting absorption or coverage, patients should consult with a healthcare professional regarding the timing of oral medications.

Q: Does Tystatin affect the heart or blood pressure?

A: Tystatin's mechanism of action is localized, but rare instances of a fast heart rate (tachycardia) have been reported as an adverse reaction. The drug is not typically associated with changes in blood pressure.

Q: Are there any lifestyle changes recommended while on Tystatin?

A: General hygienic practices, such as keeping the affected area clean and dry, are often recommended to support recovery from fungal infections. These steps can help prevent the infection from returning after the course of treatment is finished.

Q: Do patients typically need a higher or lower dose of Tystatin as they age?

A: The recommended dose for oral candidiasis in older adults is generally the same standard unit range as for younger adults and older children. There is no automatic dose adjustment specified in official guidance solely based on increasing age.

Q: Is Tystatin affected by hot or cold weather conditions?

A: Yes. Tystatin should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The oral suspension formulation must not be frozen, as this can damage the product and affect its quality.

How should Tystatin be stored and disposed of?

How to Store and Dispose of Tystatin?

Official regulatory documents define the mandatory storage and disposal requirements for Nystatin (Tystatin) to maintain its quality and ensure safety.

Official Storage Requirements

Condition Requirement
Temperature Store at 20 to 25C (68 to 77F) (Controlled Room Temperature).
Handling Avoid freezing the Oral Suspension formulation.
Packaging Keep the container tightly closed and protect from light.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Nystatin must be disposed of in accordance with local regulations for pharmaceutical waste, which may include using a drug take-back program. Generally, the medication should not be thrown away via wastewater or household trash to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tystatin found in:

A-Z Index: